Assessing the ability of DNA damage response inhibitors to prevent escape from a telomere crisis
Year: 2023
Type: dissertation
Abstract: Telomere crisis is a cellular state induced by telomere deprotection and characterised by genomic instability and cell death. Escape from telomere crisis is linked with the \ndevelopment of malignant tumours. Previous work in our lab has demonstrated that inhibition of the PARP1-induced DNA damage response can selectively kill cells undergoing \ncrisis. The aim of this thesis is to examine if inhibition of other DNA damage response pathways can affect the ability of cells to escape a telomere induced crisis and to examine \nhow this would influence cell cycle progression, apoptosis, telomere length and dynamics and DNA damage. We used colorectal cancer cells expressing a dominant-negative telomerase (DN-hTERT) that undergo a well-defined period of crisis from which they escape and we treated them with \nDNA damage response inhibitors (RAD51, RAD52, ATR, CHK1, DNA-PK, WEE1, ATM, DNA Ligase I, III and IV). We selected three inhibitors (ATR, CHK1, DNA-PK) and treated primary \nfibroblasts that undergo a well-defined period of crisis from which they do not escape. We assessed how the inhibitors affected cellular functions before and during crisis. Among the DNA damage response inhibitors tested, 50nM Rabusertib (CHK1i) consistently prevented cells escaping crisis and 50nM AZD6738 (ATRi) dramatically slowed down escape from crisis in colorectal cancer cells. The inhibitors activated the DNA damage response and they reduced cell growth, increased apoptosis and altered cell cycle progression during crisis. They did not affect the rate of telomere erosion before and during crisis, but \nRabusertib increased telomere fusion during deep crisis. Primary fibroblasts undergoing telomere crisis were sensitive to 50nM Rabusertib but not to 50nM AZD6738. \nWe propose that the ATR-CHK1 pathway is crucial in keeping cells alive during crisis and suggest further clinical evaluation of Rabusertib as a potential treatment for patients with tumours that exhibit short dysfunctional telomeres.
Author: Damo, Angelos
Institution: Cardiff University
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: green
Funders: Cancer Research Wales, Cardiff University
OpenAlex ID: W7017555352
